Mark M. Awad
0000-0003-0928-5244
Publication & Citation Trends
Publications
0 total
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Cited by 1
Semantic Scholar
MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial.
Cited by 5
Semantic Scholar
Evaluating multiplex immunofluorescence analysis of the tumor microenvironment for predicting immunotherapy efficacy in NSCLC compared to traditional biomarkers.
Cited by 0
Semantic Scholar
Abstract CT097: Associations between percent residual viable tumor (%RVT) and efficacy with perioperative nivolumab (NIVO) for resectable NSCLC in CheckMate 77T
Cited by 3
Semantic Scholar
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC
Cited by 3
Semantic Scholar
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multi-Center Retrospective Study.
Cited by 5
Semantic Scholar
PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report
Cited by 5
Semantic Scholar
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry OA
Cited by 15
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(963)
Cancer Immunotherapy and Biomarkers
(483)
Lung Cancer Research Studies
(338)
Cancer Genomics and Diagnostics
(230)
Lung Cancer Diagnosis and Treatment
(152)
Affiliations
Boston University
Genomics Institute of the Novartis Research Foundation
Brigham and Women's Hospital
Mercy St. Vincent Medical Center
Memorial Sloan Kettering Cancer Center